Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 17, 2026

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

Development, validation and testing of a human tissue engineered hypertrophic scar model.

Leonarda J van den Broek1, Frank B Niessen, Rik J Scheper

  • 1Department Dermatology, VU University Medical Center, Amsterdam, the Netherlands.

ALTEX
|November 10, 2012
PubMed
Summary

A new tissue-engineered human hypertrophic scar (HTscar) model using adipose derived mesenchymal stem cells (ASC) offers a reliable, animal-free method for testing scar-reducing therapeutics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intestine organotypic culture recapitulates human embryonic villus morphogenesis at week 8.

Tissue barriers·2026
Same author

Integrated single-cell RNA sequencing analysis reveals phenotypic differences between blood endothelial cells from oral mucosa and skin.

European journal of cell biology·2026
Same author

CD4<sup>+</sup> and CD8<sup>+</sup> T cells contribute to psoriasis phenotype when integrated into human skin equivalents for drug testing.

Frontiers in immunology·2026
Same author

A comparative study of organoid-derived and cell line-derived intestinal epithelial models.

PloS one·2026
Same author

Brain Pericytes and Wnt/β-Catenin Signaling Induce Functional Blood-Brain Barrier Phenotype in Human iPSC-Derived Model.

Small methods·2026
Same author

Diminished osteoprotegerin production by gingival fibroblasts from periodontitis patients is associated with their reduced ability to suppress osteoclastogenesis.

Scientific reports·2025

Area of Science:

  • Biomedical Engineering
  • Dermatology
  • Regenerative Medicine

Background:

  • Hypertrophic scars are a common complication of full-thickness skin wounds.
  • Existing animal and in vitro models for testing scar-reducing therapeutics are limited.
  • Adipose derived mesenchymal stem cells (ASC) play a role in scar formation.

Purpose of the Study:

  • To develop and validate a novel tissue-engineered human hypertrophic scar (HTscar) model.
  • To assess the utility of this model for testing anti-scar therapeutics.
  • To reduce reliance on animal models for scar research.

Main Methods:

  • Constructed a tissue-engineered HTscar model using reconstructed epidermis on a dermal matrix with ASC.
  • Quantified key HTscar parameters including contraction, dermal thickness, collagen-1, epidermal outgrowth, epidermal thickness, and cytokine secretion (IL-6, CXCL8).

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

Related Experiment Videos

Last Updated: May 17, 2026

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

  • Validated the model using established scar treatments (5-fluorouracil, triamcinolone), an ineffective agent (1,25-dihydroxyvitamin-D3), and potential novel agents (atorvastatin, retinoic acid).

    • Main Results:

    • The ASC-containing model successfully facilitated HTscar formation.
    • The model demonstrated sensitivity to known scar therapeutics and identified atorvastatin as a potential treatment.
    • Different therapeutics selectively impacted various scar parameters, suggesting potential for combination therapies.

    Conclusions:

    • The developed animal-free HTscar model is a viable tool for mechanistic studies and in vitro testing of anti-scar therapeutics.
    • This model can aid in the discovery of novel scar treatments and reduce animal testing.
    • Atorvastatin shows promise as a potential therapeutic for hypertrophic scar reduction.